Abiopharma

Bristol Myers Squibb - Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals forOpdivo® (nivolumab)

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

UTHR: Notification

e.l.f. Beauty Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of e.l.f. Beauty, Inc. - ELF

BellRing Brands 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against BellRing Brands, Inc. - BRBR

Pfizer Inc. - Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC